NL-OMON40083已完成不适用
Diagnostic criteria for Multiple Sclerosis: Impact of high field Magnetic Resonance Imaging - 3T-CIS Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •CIS suggestive of MS as defined by the International Panel
- •Age 18-59 years
排除标准
- •Vascular, malignant or other immunological diseases at present or in the past medical history;MRI related exclusion criteria:
- •- Claustrophobia
- •- Foreign non MR compatible metal objects in the body
- •- Foreign metal objects in or close to the head
- •- Allergic reaction to contrast administration in the past (only for patients)
研究者
相似试验
进行中（未招募）
不适用
Characterisation of multiple sclerosis pathology by ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques[Charakterisierung der Multiple Sklerose Pathologie durch ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIPPatients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first sign of MS early in the course, N=15) are planned to be investigated in the proposed clinical trial.MedDRA version: 8.1Level: LLTClassification code 10028245Term: Multiple sclerosisEUCTR2006-001337-17-DEMax-Planck-Institute of Psychiatry
已完成
不适用
Multiple sclerosis lesion characterization on ultra-high-field MRI: Comparative pilot study of 9.4 vs 7 vs 3 teslaMS10012303multiple sclerosisNL-OMON52035Zuyderland Medisch Centrum10
招募中
3 期
Patients with Multiple Sclerosis and Severe Disabilities: Effects of Electrical Stimulation Cycling Training on Mobility an Power PerformanceG35.2R26.3ImmobilityDRKS00011639Zentrum für Sensomotorik der Neurologischen Klinik,Klinikum Großhadern64
已完成
3 期
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSSpasticity, MuscleMultiple SclerosisNCT03290131RVL Pharmaceuticals, Inc.536
进行中（未招募）
3 期
Multiple Sclerosis-Simvastatin Trial 2Secondary Progressive Multiple Sclerosis (SPMS)NCT03387670University College, London964